(AOF) – Spineway has unveiled an improvement in its performance for its 2021 financial year. Net income is thus on a positive trajectory at -1.6 million euros against a loss of -14.1 million euros, last year. The operating result of the specialist in innovative implants for the treatment of severe pathologies of the spine improved by 26% compared to 2020, at -1.4 million euros. He highlighted the “good management of operating expenses carried out during the year combined with the increase in sales”.
Turnover reached 4.3 million euros, up 27%, despite a still penalizing pandemic context. This increase is driven by a fourth quarter at 1.3 million euros (+26%).
In order to finance its development projects and its operational needs, the group carried out a capital increase of 1.6 million euros during the financial year, associated with an issue premium of 11.6 million linked to its financing contract with Negma. This transaction strengthened Spineway’s equity (20.9 million) and increased cash to €13.9 million as of December 31, 2021.
Backed by its good results and an intact investment capacity, Spineway will continue its mixed growth combining organic development and targeted acquisitions.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.